Susquehanna International Group’s ASLAN Pharmaceuticals ASLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-470
Closed -$21K – 14211
2021
Q4
$21K Sell
470
-5,141
-92% -$308K ﹤0.01% 12820
2021
Q3
$399K Buy
+5,611
New +$638K ﹤0.01% 9949
2020
Q4
– Sell
-408
Closed -$31K – 11872
2020
Q3
$31K Buy
+408
New +$27.4K ﹤0.01% 10324
2020
Q2
– Sell
-569
Closed -$23K – 11136
2020
Q1
$23K Buy
569
+289
+103% +$21.9K ﹤0.01% 9909
2019
Q4
$23K Buy
+280
New +$20K ﹤0.01% 9478

Other funds holding ASLN

Susquehanna International Group's ASLN Position: Q1 2022 in Review

Susquehanna International Group sold out of ASLAN Pharmaceuticals (ASLN) in Q1 2022, closing a stake of 470 shares — an estimated $21K sold.

Susquehanna International Group first reported a position in ASLN in Q4 2019 and held it in 5 quarters. The position peaked at $399K in Q3 2021. 31 funds tracked by Wall St. Rank hold ASLN as of Q1 2022.

  • Susquehanna International Group reported no remaining ASLAN Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Susquehanna International Group sold 470 ASLAN Pharmaceuticals shares in Q1 2022, an estimated $21K.
  • Susquehanna International Group first reported a position in ASLAN Pharmaceuticals in Q4 2019 and held it in 5 quarters.
  • Susquehanna International Group's ASLAN Pharmaceuticals position peaked at $399K in Q3 2021.
  • 31 funds tracked by Wall St. Rank held ASLAN Pharmaceuticals as of Q1 2022.

Based on Susquehanna International Group's 13F filing for Q1 2022, filed 16 May 2022.